Objective:

To evaluate the efficacy and dosing considerations of low-dose atropine in managing childhood myopia.

Approach:

• Regulatory Context: Low-dose atropine has gained attention with the European approval of Ryjunea® and is supported by randomized clinical trials.
• Dose Variability: The term 'low-dose atropine' encompasses various concentrations, which may have different clinical effects.
• Trial Analysis: Existing studies vary in design, making direct comparisons difficult and complicating treatment recommendations.
• Endpoints for Success: Current trial endpoints may need to be supplemented with trajectory-based measures for better clinical interpretation.

Key Findings:

• Low-dose atropine can reduce myopia progression, but the effect varies by concentration.
• 0.05% atropine generally shows the strongest efficacy among lower doses.
• 0.01% atropine has a modest effect on axial elongation, which may not be sufficient for all patients.
• The evidence base for 0.01% atropine is substantial but should be interpreted cautiously.

Interpretation:

While low-dose atropine is effective in reducing myopia progression, the adequacy of treatment depends on individual patient factors and specific growth targets.

Limitations:

• Most existing studies were not designed to test against age-matched physiological growth targets.
• Variability in trial designs complicates the establishment of universal treatment recommendations.

Conclusion:

Further research is needed to validate trajectory-based endpoints and to determine the optimal dosing strategy for low-dose atropine in childhood myopia management.

Sources:

• European Medicines Agency